Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3199202680
